Sophiris Bio Inc. (NASDAQ:SPHS) fell 10% during mid-day trading on Wednesday . The company traded as low as $3.37 and last traded at $3.50, with a volume of 3,309,839 shares trading hands. The stock had previously closed at $3.89.

A number of brokerages recently issued reports on SPHS. Maxim Group reissued a “buy” rating and issued a $4.00 target price on shares of Sophiris Bio in a research report on Friday, June 10th. Echelon Wealth Partners reissued a “buy” rating and issued a $5.00 target price on shares of Sophiris Bio in a research report on Friday, June 10th.

The firm’s 50-day moving average price is $4.40 and its 200-day moving average price is $2.27. The company’s market capitalization is $72.86 million.

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.